LENSAR (NASDAQ:LNSR - Free Report) had its price target lifted by Lake Street Capital from $12.00 to $16.00 in a research report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.
LENSAR Price Performance
Shares of NASDAQ:LNSR traded up $0.51 on Friday, hitting $13.99. 216,169 shares of the company's stock were exchanged, compared to its average volume of 102,465. The stock has a market capitalization of $162.49 million, a price-to-earnings ratio of -9.58 and a beta of 0.66. LENSAR has a 12 month low of $2.67 and a 12 month high of $14.39. The business's 50 day simple moving average is $9.67 and its two-hundred day simple moving average is $7.16.
LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.40). The company had revenue of $16.73 million during the quarter, compared to analysts' expectations of $14.95 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of LNSR. Brandes Investment Partners LP raised its position in LENSAR by 10.4% during the 4th quarter. Brandes Investment Partners LP now owns 489,318 shares of the company's stock valued at $4,375,000 after purchasing an additional 45,920 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of LENSAR by 13.3% in the fourth quarter. Renaissance Technologies LLC now owns 348,891 shares of the company's stock valued at $3,119,000 after acquiring an additional 40,946 shares in the last quarter. Bailard Inc. bought a new stake in shares of LENSAR in the fourth quarter valued at about $181,000. Evernest Financial Advisors LLC purchased a new stake in LENSAR in the fourth quarter worth about $174,000. Finally, Essex Investment Management Co. LLC grew its holdings in LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company's stock worth $357,000 after acquiring an additional 6,184 shares in the last quarter. Institutional investors own 40.15% of the company's stock.
LENSAR Company Profile
(
Get Free Report)
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Recommended Stories
Before you consider LENSAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.
While LENSAR currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
